Citation Impact
Citing Papers
Neutralizing antibody response during acute and chronic hepatitis C virus infection
2004 StandoutNobel
Mechanisms of Viral Membrane Fusion and Its Inhibition
2001
Soluble HIV-1 Env trimers in adjuvant elicit potent and diverse functional B cell responses in primates
2010
Mapping the Antigenic and Genetic Evolution of Influenza Virus
2004 StandoutScience
Maturation-Dependent HIV-1 Surface Protein Redistribution Revealed by Fluorescence Nanoscopy
2012 StandoutScienceNobel
Antibody Domain Exchange Is an Immunological Solution to Carbohydrate Cluster Recognition
2003 Science
A Potent Cross-Clade Neutralizing Human Monoclonal Antibody against a Novel Epitope on gp41 of Human Immunodeficiency Virus Type 1
2001
Administration of nucleoside-modified mRNA encoding broadly neutralizing antibody protects humanized mice from HIV-1 challenge
2017 StandoutNobel
X4 and R5 HIV-1 Have Distinct Post-entry Requirements for Uracil DNA Glycosylase during Infection of Primary Cells
2010 StandoutNobel
Selection and analysis of an optimized anti-VEGF antibody: crystal structure of an affinity-matured fab in complex with antigen 1 1Edited by I. A. Wilson
1999
Epitope insertion into variable loops of HIV-1 gp120 as a potential means to improve immunogenicity of viral envelope protein
1999
Vector-Mediated Antibody Gene Transfer for Infectious Diseases
2015
Immunization with Envelope Subunit Vaccine Products Elicits Neutralizing Antibodies against Laboratory-Adapted but Not Primary Isolates of Human Immunodeficiency Virus Type 1
1996
Preventing infectious disease with passive immunization
2000
The β-Chemokine Receptors CCR3 and CCR5 Facilitate Infection by Primary HIV-1 Isolates
1996 Standout
DNA in a material world
2003 StandoutNature
mRNA vaccines — a new era in vaccinology
2018 StandoutNobel
Completion of the entire hepatitis C virus life cycle in genetically humanized mice
2013 StandoutNatureNobel
Dissection of human humoral immune response against hepatitis C virus E2 glycoprotein by repertoire cloning and generation of recombinant fab fragments
1998
Expanded breadth of virus neutralization after immunization with a multiclade envelope HIV vaccine candidate
2005
The antiviral activity of antibodies in vitro and in vivo
2001
Combinatorial and computational challenges for biocatalyst design
2001 StandoutNatureNobel
Chemokines — Chemotactic Cytokines That Mediate Inflammation
1998 Standout
Neutralizing Antibodies Have Limited Effects on the Control of Established HIV-1 Infection In Vivo
1999
Passive immunization with a human monoclonal antibody protects hu-PBL-SCID mice against challenge by primary isolates of HIV-1
1997
Protein Crystallization on Lipid Layers and Structure Determination of the RNA Polymerase II Transcription Initiation Complex
1999 StandoutNobel
Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus
2003 StandoutNature
The lymphocyte chemoattractant SDF-1 is a ligand for LESTR/fusin and blocks HIV-1 entry
1996 StandoutNature
Cardiovascular implications from untreated human immunodeficiency virus infection
2011
Structure of an unliganded simian immunodeficiency virus gp120 core
2005 Nature
A Limited Number of Antibody Specificities Mediate Broad and Potent Serum Neutralization in Selected HIV-1 Infected Individuals
2010
Homozygous Defect in HIV-1 Coreceptor Accounts for Resistance of Some Multiply-Exposed Individuals to HIV-1 Infection
1996 Standout
Principles for designing ideal protein structures
2012 StandoutNatureNobel
Self-assembly of DNA into nanoscale three-dimensional shapes
2009 StandoutNature
Human Antibodies from Combinatorial Libraries
1994
Neutralizing Antibody Responses to Human Immunodeficiency Virus Type 1 in Primary Infection and Long‐Term‐Nonprogressive Infection
1997
Human antibodies from phage libraries: neutralizing activity against human immunodeficiency virus type 1 equally improved after expression as Fab and IgG in mammalian cells
1996
HIV-1-resistance phenotype conferred by combination of two separate inherited mutations of CCR5 gene
1998 StandoutNobel
Antibody neutralization and escape by HIV-1
2003 StandoutNature
Decreased lesion formation in CCR2−/− mice reveals a role for chemokines in the initiation of atherosclerosis
1998 StandoutNature
Ebola virus entry requires the cholesterol transporter Niemann–Pick C1
2011 StandoutNature
Promise and problems associated with the use of recombinant AAV for the delivery of anti-HIV antibodies
2016
Structural Details of HIV-1 Recognition by the Broadly Neutralizing Monoclonal Antibody 2F5: Epitope Conformation, Antigen-Recognition Loop Mobility, and Anion-Binding Site
2008
Membrane Fusion
2003 StandoutNobel
Super-resolution biomolecular crystallography with low-resolution data
2010 StandoutNatureNobel
Human Immunodeficiency Virus Type 1 Neutralizing Antibody Serotyping Using Serum Pools and an Infectivity Reduction Assay
1996
Surrogate Wnt agonists that phenocopy canonical Wnt and β-catenin signalling
2017 StandoutNatureNobel
From catalytic asymmetric synthesis to the transcriptional regulation of genes: In vivo and in vitro evolution of proteins
2001 StandoutNobel
Mutations That Destabilize the gp41 Core Are Determinants for Stabilizing the Simian Immunodeficiency Virus-CPmac Envelope Glycoprotein Complex
2002
Neutralizing antibodies generated during natural HIV-1 infection: good news for an HIV-1 vaccine?
2009
Structural definition of a conserved neutralization epitope on HIV-1 gp120
2007 Nature
Design and self-assembly of two-dimensional DNA crystals
1998 StandoutNature
Understanding the hepatitis C virus life cycle paves the way for highly effective therapies
2013 StandoutNobel
Heterologous Epitope-Scaffold Prime∶Boosting Immuno-Focuses B Cell Responses to the HIV-1 gp41 2F5 Neutralization Determinant
2011 StandoutNobel
The CXC chemokine SDF-1 is the ligand for LESTR/fusin and prevents infection by T-cell-line-adapted HIV-1
1996 StandoutNature
Epitope specificities of broadly neutralizing plasmas from HIV-1 infected subjects
2010
Decay characteristics of HIV-1-infected compartments during combination therapy
1997 StandoutNature
HIV-1 Neutralization Profile and Plant-Based Recombinant Expression of Actinohivin, an Env Glycan-Specific Lectin Devoid of T-Cell Mitogenic Activity
2010 StandoutNobel
Recombinant HIV Envelope Proteins Fail to Engage Germline Versions of Anti-CD4bs bNAbs
2013
Angiogenesis as a therapeutic target
2005 StandoutNature
Manufacturing Immunity to Disease in a Test Tube: The Magic Bullet Realized
2006
Follicular dendritic cells and human immunodeficiency virus infectivity
1995 Nature
Circumventing tolerance to generate autologous monoclonal antibodies to the prion protein.
1996 StandoutNobel
Designed Two-Dimensional DNA Holliday Junction Arrays Visualized by Atomic Force Microscopy
1999
Human monoclonal antibody 2G12 defines a distinctive neutralization epitope on the gp120 glycoprotein of human immunodeficiency virus type 1
1996
The Mannose-Dependent Epitope for Neutralizing Antibody 2G12 on Human Immunodeficiency Virus Type 1 Glycoprotein gp120
2002
Computation-Guided Backbone Grafting of a Discontinuous Motif onto a Protein Scaffold
2011 StandoutScienceNobel
Replicative function and neutralization sensitivity of envelope glycoproteins from primary and T-cell line-passaged human immunodeficiency virus type 1 isolates
1995
Comprehensive Cross-Clade Neutralization Analysis of a Panel of Anti-Human Immunodeficiency Virus Type 1 Monoclonal Antibodies
2004
Rational HIV Immunogen Design to Target Specific Germline B Cell Receptors
2013 StandoutScienceNobel
Inhibition of Virus Attachment to CD4+ Target Cells Is a Major Mechanism of T Cell Line–adapted HIV-1 Neutralization
1997
Recognition properties of a panel of human recombinant Fab fragments to the CD4 binding site of gp120 that show differing abilities to neutralize human immunodeficiency virus type 1
1994
Construction, Analysis, Ligation, and Self-Assembly of DNA Triple Crossover Complexes
2000
Anti-HIV B Cell Lines as Candidate Vaccine Biosensors
2012
Human broadly neutralizing antibodies to the envelope glycoprotein complex of hepatitis C virus
2012 StandoutNobel
Broadly neutralizing antibodies abrogate established hepatitis C virus infection
2014 StandoutNobel
Fine Mapping of the Interaction of Neutralizing and Nonneutralizing Monoclonal Antibodies with the CD4 Binding Site of Human Immunodeficiency Virus Type 1 gp120
2002
Antibodies in HIV-1 Vaccine Development and Therapy
2013 Science
Persistent infection of macaques with simian-human immunodeficiency viruses
1995
Broadly Neutralizing Antibodies Present New Prospects to Counter Highly Antigenically Diverse Viruses
2012 Science
Block Copolymer Lithography: Periodic Arrays of ~10 11 Holes in 1 Square Centimeter
1997 StandoutScience
Recombinant human monoclonal antibodies against different conformational epitopes of the E2 envelope glycoprotein of hepatitis C virus that inhibit its interaction with CD81
2000 StandoutNobel
Rapid evolution of the neutralizing antibody response to HIV type 1 infection
2003
Site-specific chemical modification of recombinant proteins produced in mammalian cells by using the genetically encoded aldehyde tag
2009 StandoutNobel
Potent and synergistic neutralization of human immunodeficiency virus (HIV) type 1 primary isolates by hyperimmune anti-HIV immunoglobulin combined with monoclonal antibodies 2F5 and 2G12
1997
Cross-clade neutralization of primary isolates of human immunodeficiency virus type 1 by human monoclonal antibodies and tetrameric CD4-IgG
1995
Anti-HIV-1 and chemotactic activities of human stromal cell-derived factor 1α (SDF-1α) and SDF-1β are abolished by CD26/dipeptidyl peptidase IV-mediated cleavage
1998 StandoutNobel
Autologous and heterologous neutralizing antibody responses following initial seroconversion in human immunodeficiency virus type 1-infected individuals
1997
Analysis of Neutralization Specificities in Polyclonal Sera Derived from Human Immunodeficiency Virus Type 1-Infected Individuals
2008
Redox-Triggered Infection by Disulfide-Shackled Human Immunodeficiency Virus Type 1 Pseudovirions
2003
Dissecting the Neutralizing Antibody Specificities of Broadly Neutralizing Sera from Human Immunodeficiency Virus Type 1-Infected Donors
2007
Initiation of Antiretroviral Therapy in Early Asymptomatic HIV Infection
2015 Standout
Genetic Restriction of HIV-1 Infection and Progression to AIDS by a Deletion Allele of the CKR5 Structural Gene
1996 StandoutScience
Structural basis for germ-line gene usage of a potent class of antibodies targeting the CD4-binding site of HIV-1 gp120
2012
Computational Design of Proteins Targeting the Conserved Stem Region of Influenza Hemagglutinin
2011 StandoutScienceNobel
The HIV-1 Envelope Glycoproteins: Fusogens, Antigens, and Immunogens
1998 StandoutScience
Broadly neutralizing anti-HIV-1 antibodies disrupt a hinge-related function of gp41 at the membrane interface
2009
Lipid nanotubes as substrates for helical crystallization of macromolecules
1998
Mechanism by which the lectin actinohivin blocks HIV infection of target cells
2009 StandoutNobel
GP120: Biologic Aspects of Structural Features
2001
Inter- and intraclade neutralization of human immunodeficiency virus type 1: genetic clades do not correspond to neutralization serotypes but partially correspond to gp120 antigenic serotypes
1996
Structural basis for Zika envelope domain III recognition by a germline version of a recurrent neutralizing antibody
2020 StandoutNobel
A fusion-intermediate state of HIV-1 gp41 targeted by broadly neutralizing antibodies
2008
Engineering human hematopoietic stem/progenitor cells to produce a broadly neutralizing anti-HIV antibody after in vitro maturation to human B lymphocytes.
2008 Nobel
Discovery of cyanovirin-N, a novel human immunodeficiency virus-inactivating protein that binds viral surface envelope glycoprotein gp120: potential applications to microbicide development
1997
Antiparallel DNA Double Crossover Molecules As Components for Nanoconstruction
1996
Neutralizing Monoclonal Antibodies Block Human Immunodeficiency Virus Type 1 Infection of Dendritic Cells and Transmission to T Cells
1998 StandoutNobel
Ebola Virus Can Be Effectively Neutralized by Antibody Produced in Natural Human Infection
1999
Increased Neutralization Sensitivity of CD4-Independent Human Immunodeficiency Virus Variants
2001
Progress toward active or passive HIV-1 vaccination
2016
Elicitation of structure-specific antibodies by epitope scaffolds
2010 StandoutNobel
Integrin αvβ3‐targeted therapy for Kaposi's sarcoma with an in vitro‐evolved antibody
2002
Primary isolates of human immunodeficiency virus type 1 are relatively resistant to neutralization by monoclonal antibodies to gp120, and their neutralization is not predicted by studies with monomeric gp120
1995
Role of HIV membrane in neutralization by two broadly neutralizing antibodies
2009
The Broadly Neutralizing Anti-Human Immunodeficiency Virus Type 1 Antibody 2G12 Recognizes a Cluster of α1→2 Mannose Residues on the Outer Face of gp120
2002
Works of Lynette Sawyer being referenced
Passive Infusion of Immune Serum into Simian Immunodeficiency Virus-Infected Rhesus Macaques Undergoing a Rapid Disease Course Has Minimal Effect on Plasma Viremia
2000
Distribution of HIV type 1 (HIV‐1) in blood components: detection and significance of high levels of HIV‐1 associated with platelets
1998
Efficient Neutralization of Primary Isolates of HIV-1 by a Recombinant Human Monoclonal Antibody
1994 Science
Neutralizing antibody responses to autologous and heterologous isolates of human immunodeficiency virus.
1994
In vitro evolution of a neutralizing human antibody to human immunodeficiency virus type 1 to enhance affinity and broaden strain cross-reactivity.
1994
Postexposure immunoprophylaxis of primary isolates by an antibody to HIV receptor complex
1999